Abcam, ab211495, Anti-2-methyladenosine (m2A) antibody [EPR -19851-59]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal 2-methyladenosine (m2A) antibody. Suitable for IP, ELISA and reacts with Modified Nucleic Acid samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR -19851-59,
Isotype:IgG,
Carrier free:No,
Applications:IP, ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Has been developed to discriminate between the modified base 2-methyladenosine (m2A) and the unmodified counterpart Adenosine (A).

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
2-methyladenosine (m2A) is a modified nucleoside that plays a significant role in RNA structures impacting RNA stability and function. It is an adenosine derivative where a methyl group is added to the nitrogen at position 2 of the adenine ring altering its chemical properties. This modification has a relatively small molecular mass of approximately 281.3 Da. m2A is found primarily in tRNA and rRNA molecules within the cell contributing to their proper folding and stability. It is ubiquitously expressed across various tissues reflecting its broad functional significance.
Biological function summary
The modification of RNA by 2-methyladenosine contributes significantly to RNA processing and function. It plays a role in the structural integrity and proper folding of tRNA and rRNA by maintaining the stability of the RNA molecules they modify. m2A acts within ribonucleoprotein complexes where it influences the recognition and interaction between RNA and protein components. This modification ensures the accuracy of translation by maintaining the correct conformation of the RNA molecules involved in protein synthesis.
Pathways
2-methyladenosine engages in essential biological processes such as translation and RNA processing. It is involved in the ribosome biogenesis pathway which is important for protein synthesis in cells. Within this pathway m2A interacts with other RNA modifications and proteins like the ribosomal proteins and various RNA-binding proteins that guide RNA through the maturation process. The presence of m2A aids the efficient assembly of ribosomal units necessary for the synthesis of proteins.
Altered levels of 2-methyladenosine have been implicated in disorders related to dysfunction in protein synthesis. Aberrant m2A modification has been linked to certain cancers wherein improper RNA processing might contribute to uncontrolled cellular proliferation. Additionally it relates to neurodegenerative diseases where misfolded proteins result from translation dysregulation. In this context m2A modifications can affect the function of proteins such as ribosome-associated proteins and those involved in RNA methylation influencing disease outcomes through changes in RNA stability and processing.